Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

7.650
-0.070-0.91%
Volume:5.47M
Turnover:41.23M
Market Cap:7.37B
PE:-23.32
High:7.790
Open:7.380
Low:7.220
Close:7.720
Loading ...

Ascletis Doses First Patients for US Trial of Obesity Drug Combo

MT Newswires Live
·
21 May

HK Movers | HK's Biotech Shares Soar. Asymchem up 15%; Laekna up 13%; Ascletis, CanSinoBIO up 9%

Tiger Newspress
·
21 May

BRIEF-Ascletis Announces First Participants Dosed In A U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, And Semaglutide For The Treatment Of Obesity

Reuters
·
20 May

Ascletis Pharma Initiates U.S. Clinical Study Combining ASC47 and Semaglutide for Obesity Treatment

Reuters
·
20 May

Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule ThrΒ Agonist, Asc47, and Semaglutide for the Treatment of Obesity

THOMSON REUTERS
·
20 May

Ascletis Pharma Inc - Topline Data From Study Expected in Q4 2025

THOMSON REUTERS
·
20 May

HK Movers | HK's Biotech Shares Soar. Cstone Pharma Soars 20%; RemeGen up 10%; Ascletis up 6%

Tiger Newspress
·
20 May

HK Movers | HK's Biotech Shares Pull Back. Alphamab, Cstone Pharma, Ascletis down about 10%; Immuneonco, Laekna down over 9%

Tiger Newspress
·
12 May

Ascletis Pharma to Present Results of Preliminary Studies on Anti-Obesity Drug

MT Newswires Live
·
06 May

Ascletis Pharma's Phase 1B Trial for Obesity Tablets Showed Favorable Safety Results

MT Newswires Live
·
23 Apr

HK Movers | Biotech Stocks Rally With Zai Lab up 8%

Tiger Newspress
·
23 Apr

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30 and Submission of 13-Week Phase Iia Study Protocol to FDA

THOMSON REUTERS
·
23 Apr

HK Movers|HK Pharma Stocks Shined. Ascletis up 18%; Dualitybio up 8%; Zai Lab, HBM and Remegen Up 6%.

Tiger Newspress
·
22 Apr

Ascletis Pharma Reports Positive Interim Results for Obesity Treatment; Shares Up 6%

MT Newswires Live
·
01 Apr

BRIEF-Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

Reuters
·
31 Mar

Ascletis Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30, a Potentially First-in-Class Subcutaneous Injection Small Molecule Glp-1R Agonist

THOMSON REUTERS
·
31 Mar

Ascletis Pharma Inc - Asc30 Sq Injection Shows 36-Day Half-Life in Obesity Patients

THOMSON REUTERS
·
31 Mar

Ascletis Pharma: Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30

THOMSON REUTERS
·
31 Mar

Ascletis Pharma's Attributable Loss Widens in 2024 as Revenue Plummets

MT Newswires Live
·
27 Mar

Ascletis Pharma FY Revenue RMB 1.3 Million

THOMSON REUTERS
·
26 Mar